1427 ET - WELL Health Technologies is set to continue its acquisitive momentum in 2025, and TD Cowen's David Kwan thinks WELL's unannounced additions could be positive for the balance sheet. In a report, the analyst says that these could account for almost C$75 million in revenue and C$8-C$9 million in Ebitda, which would represent about 6% upside to TD's current forecasts. Kwan says WELL's current M&A pipeline includes 12 letters-of-intent reflecting C$65 million in revenue and in-line Ebitda margins. "With a continued robust M&A pipeline, we believe WELL will remain active with its M&A program that should help it drive strong, profitable growth," Kwan says. Shares are up 1.2% to C$6.70. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
January 14, 2025 14:27 ET (19:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.